Physical Address
304 North Cardinal St.
Dorchester Center, MA 02124
After these transactions, Dierks no longer owns shares in the company. Harmony (JO:) Biosciences, which maintains good financial health data to follow InvestingPro data, it has more capital than debt on its balance sheet and shows strong liquidity with a current ratio of 3.24. The pharmaceutical company continues to focus on developing and commercializing new treatments for patients with rare neurological diseases.
After these transactions, Dierks no longer owns shares in the company. Harmony Biosciences, which maintains good financial health information to follow InvestingPro data, it has more capital than debt on its balance sheet and shows strong liquidity with a current ratio of 3.24. The pharmaceutical company continues to focus on developing and commercializing new treatments for patients with rare neurological diseases.
After these transactions, Dierks no longer owns shares in the company. Harmony Biosciences, which maintains good financial health information to follow InvestingPro data, it has more capital than debt on its balance sheet and shows strong liquidity with a current ratio of 3.24. The pharmaceutical company continues to focus on developing and commercializing new treatments for patients with rare neurological diseases.
In other recent news, Harmony Biosciences reported strong earnings for Q4 2024, with revenue coming in at around $201 million, matching HC Wainwright’s estimate and above consensus of $712 million. The company also expects revenue of about $714 billion for the full year of 2024. Looking ahead, Harmony provided a revenue forecast for 2025, estimating between $820 million and $860 million.
In addition to financial performance, Harmony Biosciences has made significant progress in its product portfolio. The company is awaiting a decision from the FDA on the supplemental New Drug Application for WAKIX, their lead product, to treat idiopathic hypersomnia, which is expected in the first quarter of 2025. Progress is expected more, including the possible introduction of the first person. studies of BP1.15205, an OX2R agonist, in the third quarter of 2025, and top results from a pivotal Phase 3 trial evaluating ZYN002 in Fragile X syndrome in the third quarter of 2025.
Analysts at HC Wainwright and Oppenheimer reaffirmed their confidence in the company, maintaining Buy and Outperform ratings, respectively. The former has a price target of $75.00 for the company’s stock, while the latter raised its price target from $59 to $61. These estimates reflect analysts’ expectations of Harmony Biosciences’ development and growth opportunities.
This article was created with the support of AI and reviewed by the editor. For more details, see our T&C.
